Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Journals
Alzheimer's & Dementia : the J...
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
#1
JOURNAL ARTICLE
Lavanya Jain, Maria Khrestian, Shane Formica, Elizabeth D Tuason, Jagan A Pillai, Stephen Rao, Odinachi Oguh, Carol F Lippa, Oscar L Lopez, Sarah B Berman, Debby W Tsuang, Cyrus P Zabetian, David J Irwin, Douglas R Galasko, Irene Litvan, Karen S Marder, Lawrence S Honig, Jori E Fleisher, James E Galvin, Andrea C Bozoki, Angela S Taylor, Marwan N Sabbagh, James B Leverenz, Lynn M Bekris
INTRODUCTION: The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis. METHODS: The cohort was subtyped by cerebrospinal fluid (CSF) ATN category...
September 23, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#2
JOURNAL ARTICLE
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network.
Olivia Wagemann, Yan Li, Jason Hassenstab, Andrew J Aschenbrenner, Nicole S McKay, Brian A Gordon, Tammie L S Benzinger, Chengjie Xiong, Carlos Cruchaga, Alan E Renton, Richard J Perrin, Sarah B Berman, Jasmeer P Chhatwal, Martin R Farlow, Gregory S Day, Takeshi Ikeuchi, Mathias Jucker, Francisco Lopera, Hiroshi Mori, James M Noble, Raquel Sánchez-Valle, Peter R Schofield, John C Morris, Alisha Daniels, Johannes Levin, Randall J Bateman, Eric McDade, Jorge J Llibre-Guerra
INTRODUCTION: Studies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females and males. We investigated sex differences in cognition, neuroimaging, and fluid biomarkers in dominantly inherited AD (DIAD). METHODS: Three hundred twenty-five mutation carriers (55% female) and one hundred eighty-six non-carriers (58% female) of the Dominantly Inherited Alzheimer Network Observational Study were analyzed...
September 23, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#3
JOURNAL ARTICLE
Cassandra Morrison, Mahsa Dadar, Donald Louis Collins
BACKGROUND: White matter hyperintensities (WMHs) are associated with cognitive decline and progression to mild cognitive impairment (MCI) and dementia. It remains unclear if sex differences influence WMH progression or the relationship between WMH and cognition. METHODS: Linear mixed models examined the relationship between risk factors, WMHs, and cognition in males and females. RESULTS: Males exhibited increased WMH progression in occipital, but lower progression in frontal, total, and deep than females...
September 21, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#4
JOURNAL ARTICLE
Albert Puig-Pijoan, Joan Jimenez-Balado, Aida Fernández-Lebrero, Greta García-Escobar, Irene Navalpotro-Gómez, Jose Contador, Rosa-María Manero-Borràs, Victor Puente-Periz, Antoni Suárez, Francisco J Muñoz, Oriol Grau-Rivera, Marc Suárez-Calvet, Rafael de la Torre, Jaume Roquer, Angel Ois
INTRODUCTION: This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort. METHODS: This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored...
September 19, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#5
JOURNAL ARTICLE
Katia de Paiva Lopes, Lei Yu, Xianli Shen, Yiguo Qiu, Shinya Tasaki, Artemis Iatrou, Michal Schnaider Beeri, Nicholas T Seyfried, Vilas Menon, Yanling Wang, Julie A Schneider, Harvey Cantor, David A Bennett
INTRODUCTION: The secreted phosphoprotein 1 (SPP1) gene expressed by CD11c+ cells is known to be associated with microglia activation and neuroinflammatory diseases. As most studies rely on mouse models, we investigated these genes and proteins in the cortical brain tissue of older adults and their role in Alzheimer's disease (AD) and related disorders. METHODS: We leveraged protein measurements, single-nuclei, and RNASeq data from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) of over 1200 samples for association analysis...
September 19, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#6
LETTER
Samuele Bonomi, Mahendra R Gupta, Suzanne E Schindler
No abstract text is available yet for this article.
September 18, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#7
JOURNAL ARTICLE
Raj G Kumar, Evan Bollens Lund, Katherine A Ornstein, Jing Li, Kenneth E Covinsky, Amy S Kelley
INTRODUCTION: There is evidence that health care utilization increases after incident dementia, particularly after dementia diagnosis and toward the end of life; however, less is known about utilization in the years before dementia identification. METHODS: In this retrospective cohort study we obtained data on n = 5547 beneficiaries from the Health and Retirement Study (HRS)-Medicare linked sample (n = 1241 with and n = 4306 without dementia) to compare longitudinal trends in health care costs and utilization in the 6 years preceding dementia identification relative to a confounder-balanced reference group without dementia...
September 18, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#8
REVIEW
Dallas P Veitch, Michael W Weiner, Melanie Miller, Paul S Aisen, Miriam A Ashford, Laurel A Beckett, Robert C Green, Danielle Harvey, Clifford R Jack, William Jagust, Susan M Landau, John C Morris, Kwangsik T Nho, Rachel Nosheny, Ozioma Okonkwo, Richard J Perrin, Ronald C Petersen, Monica Rivera Mindt, Andrew Saykin, Leslie M Shaw, Arthur W Toga, Duygu Tosun
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use...
September 12, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#9
JOURNAL ARTICLE
Joseph E Gaugler, Soo Borson, Fayron Epps, Regina A Shih, Lauren J Parker, Lisa C McGuire
In this Perspective article, we highlight current research to illustrate the intersection of social determinants of health (SDOHs) and Alzheimer's disease and related dementia (ADRD) caregiving. We then outline how public health can support ADRD family caregivers in the United States. Emerging research suggests that family care for persons with ADRD is influenced by SDOHs. Public health actions that address these intersections such as improved surveillance and identification of ADRD caregivers; building and enhancing community partnerships; advancing dementia-capable health care and related payment incentives; and reducing the stigma of dementia and ADRD caregiving can potentially enhance the health and well-being of dementia caregivers...
September 12, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#10
JOURNAL ARTICLE
Kai Chen, Riya Gupta, Alejandro Martín-Ávila, Meng Cui, Zhongcong Xie, Guang Yang
INTRODUCTION: Anesthesia often exacerbates memory recall difficulties in individuals with Alzheimer's disease (AD), but the underlying mechanisms remain unclear. METHODS: We used in vivo Ca2+ imaging, viral-based circuit tracing, and chemogenetic approaches to investigate anesthesia-induced remote memory impairment in mouse models of presymptomatic AD. RESULTS: Our study identified pyramidal neuron hyperactivity in the anterior cingulate cortex (ACC) as a significant contributor to anesthesia-induced remote memory impairment...
September 11, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#11
JOURNAL ARTICLE
Klevest Gjini, Cameron Casey, David Kunkel, Maihlee Her, Matthew I Banks, Robert A Pearce, Richard Lennertz, Robert D Sanders
INTRODUCTION: Post-operative delirium (POD) is associated with increased morbidity and mortality but is bereft of treatments, largely due to our limited understanding of the underlying pathophysiology. We hypothesized that delirium reflects a disturbance in cortical connectivity that leads to altered predictions of the sensory environment. METHODS: High-density electroencephalogram recordings during an oddball auditory roving paradigm were collected from 131 patients...
September 11, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#12
REVIEW
Kaj Blennow, Douglas Galasko, Robert Perneczky, Frances-Catherine Quevenco, Wiesje M van der Flier, Akin Akinwonmi, Margherita Carboni, Alexander Jethwa, Ivonne Suridjan, Henrik Zetterberg
INTRODUCTION: Many people with cognitive complaints or impairment never receive an accurate diagnosis of the underlying condition, potentially impacting their access to appropriate treatment. To address this unmet need, plasma biomarker tests are being developed for use in Alzheimer's disease (AD). Plasma biomarker tests span various stages of development, including in vitro diagnostic devices (or tests) (IVDs), laboratory-developed tests (LDTs) and research use only devices (or tests) (RUOs)...
September 11, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#13
JOURNAL ARTICLE
Hanna Cho, Nidhi S Mundada, Liana G Apostolova, Maria C Carrillo, Ranjani Shankar, Alinda N Amuiri, Ehud Zeltzer, Charles C Windon, David N Soleimani-Meigooni, Jeremy A Tanner, Courtney Lawhn Heath, Orit H Lesman-Segev, Paul Aisen, Ani Eloyan, Hye Sun Lee, Dustin B Hammers, Kala Kirby, Jeffrey L Dage, Anne Fagan, Tatiana Foroud, Lea T Grinberg, Clifford R Jack, Joel Kramer, Walter A Kukull, Melissa E Murray, Kelly Nudelman, Arthur Toga, Prashanthi Vemuri, Alireza Atri, Gregory S Day, Ranjan Duara, Neill R Graff-Radford, Lawrence S Honig, David T Jones, Joseph Masdeu, Mario Mendez, Erik Musiek, Chiadi U Onyike, Meghan Riddle, Emily J Rogalski, Stephen Salloway, Sharon Sha, Raymond Scott Turner, Thomas S Wingo, David A Wolk, Robert Koeppe, Leonardo Iaccarino, Bradford C Dickerson, Renaud La Joie, Gil D Rabinovici
INTRODUCTION: We aimed to describe baseline amyloid-beta (Aβ) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD). METHODS: We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years...
September 10, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#14
JOURNAL ARTICLE
Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Carolina Minguillón, Karine Fauria, Jose Luis Molinuevo, Oriol Grau-Rivera, Armand González Escalante, Gwendlyn Kollmorgen, Margherita Carboni, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet, Juan Domingo Gispert
INTRODUCTION: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. METHODS: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. RESULTS: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL)...
September 10, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#15
JOURNAL ARTICLE
Lasse S Madsen, Pernille L Kjeldsen, Rola Ismail, Peter Parbo, Leif Østergaard, David J Brooks, Simon F Eskildsen
INTRODUCTION: Capillary dysfunction, characterized by disturbances in capillary blood flow distribution, might be an overlooked factor in the development of Alzheimer's disease (AD). This study investigated microvascular blood flow in preclinical and prodromal AD individuals. METHODS: Using dynamic susceptibility contrast magnetic resonance imaging and positron emission tomography, we examined alterations in microvascular circulation and levels of Aβ deposition in two independent cohorts of APOE ε4 carriers...
September 7, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#16
JOURNAL ARTICLE
Shannon Halloway, Maude Wagner, Christy Tangney, Brittney S Lange-Maia, David A Bennett, Zoe Arvanitakis, Michael E Schoeny
INTRODUCTION: We aimed to identify profiles of modifiable, late-life lifestyle health behaviors related to subsequent maintenance of cognition and explore sociodemographics and health characteristics as effect modifiers. METHODS: Analyses used data from 715 older adults without baseline dementia from the Rush Memory and Aging Project and with lifestyle health behaviors (physical activity, cognitive activity, healthy diet, social activity) at baseline and ≥ 2 annual assessments of cognition...
September 7, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#17
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 7, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#18
JOURNAL ARTICLE
Danial Qureshi, Jennifer Collister, Naomi E Allen, Elżbieta Kuźma, Thomas Littlejohns
INTRODUCTION: The association between metabolic syndrome (MetS) and incident dementia remains inconclusive. METHODS: In 176,249 dementia-free UK Biobank participants aged ≥60 years at baseline, Cox proportional-hazards models were used to investigate the association between MetS and incident dementia. MetS was defined as the presence of ≥3 of the following: elevated waist circumference, triglycerides, blood pressure, blood glucose, and reduced high-density lipoprotein cholesterol...
September 7, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#19
JOURNAL ARTICLE
Breton M Asken, Wei-En Wang, Karen McFarland, Franchesca Arias, Jacob Fiala, Idaly Velez-Uribe, Robin P Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Michael Marsiske, Monica Rosselli, Warren W Barker, Rosie Curiel Cid, David A Loewenstein, Steven T DeKosky, Melissa J Armstrong, Glenn E Smith, Malek Adjouadi, David E Vaillancourt, Ranjan Duara
INTRODUCTION: Alzheimer's disease studies often lack ethnic diversity. METHODS: We evaluated associations between plasma biomarkers commonly studied in Alzheimer's (p-tau181, GFAP, and NfL), clinical diagnosis (clinically normal, amnestic MCI, amnestic dementia, or non-amnestic MCI/dementia), and Aβ-PET in Hispanic and non-Hispanic older adults. Hispanics were predominantly of Cuban or South American ancestry. RESULTS: Three-hundred seventy nine participants underwent blood draw (71...
September 6, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#20
JOURNAL ARTICLE
Duygu Tosun, Ozlem Yardibi, Tammie L S Benzinger, Walter A Kukull, Colin L Masters, Richard J Perrin, Michael W Weiner, Arthur Simen, Adam J Schwarz
INTRODUCTION: Biomarkers remain mostly unavailable for non-Alzheimer's disease neuropathological changes (non-ADNC) such as transactive response DNA-binding protein 43 (TDP-43) proteinopathy, Lewy body disease (LBD), and cerebral amyloid angiopathy (CAA). METHODS: A multilabel non-ADNC classifier using magnetic resonance imaging (MRI) signatures was developed for TDP-43, LBD, and CAA in an autopsy-confirmed cohort (N = 214). RESULTS: A model using demographic, genetic, clinical, MRI, and ADNC variables (amyloid positive [Aβ+] and tau+) in autopsy-confirmed participants showed accuracies of 84% for TDP-43, 81% for LBD, and 81% to 93% for CAA, outperforming reference models without MRI and ADNC biomarkers...
September 4, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
